STUDYING OF RADIATION SAFETY OF 188Re-LABELED MAA PREPARATION FOR TREATMENT OF RESISTANT SYNOVITIS

The article is written about studying of radiation safety of 188Re-labeled microspheres of albumin preparation (hand mode) for treatment of resistant synovitis. The study material was a radiopharmaceutical based on albumin microspheres 5 –10 µm with rhenium-188 for treatment of resistant synovitis. The studying has led to conclusion the number of radiopharmaceutical portions prepared by one operator should not exceed 70 times a year, which will ensure that the main limits of equivalent doses to hands and skin with a reserve factor of 2 (250 μSv/h) are not exceeded. Protective equipment should be used to reduce doses to hands, as the most critical to operator's body part irradiation.

Nanoparticles of Conjugated Methotrexate-Human Serum Albumin: Preparation and Cytotoxicity Evaluations

Methotrexate-human serum albumin conjugates were developed by a simple carbodiimide reaction. Methotrexate-human serum albumin conjugates were then crosslinked with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDC) to form nanoparticles. The size of nanoparticles determined by laser light scattering and TEM was between 90–150 nm. Nanoparticles were very stable at physiologic conditions (PBS pH 7.4, ) and after incubation with serum. The effect of amount of EDC used for crosslinking on the particle size and free amino groups of nanoparticles was examined. The amount of crosslinker showed no significant effect on the size of nanoparticles but free amino groups of nanoparticles were decreased by increasing the crosslinker. The physicochemical interactions between methotrexate and human serum albumin were investigated by differential scanning calorimetry (DSC). Nanoparticles were more cytotoxic on T47D cells compared to free methotrexate. Moreover, methotrexate-human serum albumin nanoparticles decreased the IC50 value of methotrexate on T47D cells in comparison with free methotrexate.